Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
Status:
Recruiting
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
The study investigates, whether the patient group with intermediate-risk early breast cancer
benefits from treatment with ribociclib in combination with endocrine therapy compared to
standard-of-care chemotherapy (followed by adjuvant endocrine therapy).